[Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider transactions by John R. Moore at Edgewise Therapeutics (EWTX): The reporting person, General Counsel John R. Moore, recorded transactions on 08/12/2025 showing both equity compensation vesting and a small sale to cover taxes. He had 5,781 RSUs vest (treated as acquired) and sold 2,098 shares in a sell-to-cover at an average price of $13.3924 (trade prices ranged $13.36–$13.49). Following these transactions, Mr. Moore directly beneficially owned 17,344 shares plus outstanding awards and options.

Compensation grants: New awards include 26,875 RSUs (vesting from 08/12/2026) and a 161,250-share stock option with a $13.39 exercise price vesting monthly from 09/12/2025 through 08/12/2035.

Insights

Financial Analyst

TL;DR: Insider received substantial equity compensation and performed a routine sell-to-cover; impact on share count is modest but notable for governance.

These filings show standard executive compensation: immediate vesting of 5,781 RSUs with a tax-related sale of 2,098 shares and larger future-focused grants (26,875 RSUs and a 161,250-option award at $13.39). The option grant is sizeable relative to the reported holdings and creates potential dilution if exercised; however, the sell-to-cover was not a market-disruptive disposition. For investors, this is a routine disclosure of alignment via long-term incentives rather than an operational signal.

Corporate Governance Expert

TL;DR: Governance-wise, the filing reflects customary executive compensation and a pre-approved sell-to-cover tax withholding, with no red flags.

The transaction footnotes clarify the sale met statutory tax withholding and was not discretionary, which is an affirmative disclosure practice. The time-based vesting schedules (annual RSU tranches and monthly option vesting) align executive retention with long-term shareholder interests. There is no indication of related-party or off-market pricing beyond the stated exercise price and average sale price range.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOORE JOHN R

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/12/2025		M		5,781	A	$0.00	12,312	D
Common Stock	08/12/2025		S		2,098(1)	D	$13.3924(2)	10,214	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0.00	08/12/2025		M			5,781	(3)	08/12/2034	Common Stock	5,781	$0.00	17,344	D
Restricted Stock Units	$0.00	08/12/2025		A		26,875		(4)	08/12/2035	Common Stock	26,875	$0.00	26,875	D
Stock Option (Right to Buy)	$13.39	08/12/2025		A		161,250		(5)	08/12/2035	Common Stock	161,250	$0.00	161,250	D

Explanation of Responses:

1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $13.36 to $13.49, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.

4. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.

5. 1/48th of the shares subject to the option vest each month beginning on September 12, 2025, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/ John R. Moore	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did John R. Moore report on Form 4 for EWTX?

The filing reports vesting of 5,781 RSUs, a sell-to-cover of 2,098 shares at an average price of $13.3924, grants of 26,875 RSUs, and a 161,250-share option with a $13.39 exercise price.

Why were 2,098 shares sold according to the Form 4?

The sale of 2,098 shares was a sell-to-cover transaction to satisfy statutory tax withholding on vested RSUs, not a discretionary sale.

When do the new RSUs and options vest for EWTX insider grants?

The 5,781 vested RSUs had four equal annual installments beginning 08/12/2025; the 26,875 RSUs vest in four equal annual installments beginning 08/12/2026; the 161,250-option vests monthly beginning 09/12/2025.

What is the exercise price and term of the stock option reported?

The reported stock option has an exercise price of $13.39 and an expiration tied to 08/12/2035 per the schedule reported.